Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15517268 | 0.76 | NOTUM (0.34) | GLAPOLBGAATSHR | |
| SCHEMBL6756054 | 0.74 | CES2 (0.41) | GLAPOLBGAATSHR | |
| SCHEMBL23416481 | 0.73 | GAA (0.35) | GLAPOLBGAATSHR | |
| SCHEMBL3032982 | 0.72 | CES2 (0.31) | GLAPOLBGAATSHR | |
| SCHEMBL392404 | 0.72 | TSHR (0.52) | GLAPOLBGAATSHR | |
| SCHEMBL7657209 | 0.72 | SMN1; SMN2 (0.39) | GLAPOLBGAATSHR | |
| SCHEMBL1008442 | 0.72 | DAO (0.34) | — | |
| SCHEMBL14302780 | 0.72 | GLA (0.31) | GLAPOLBGAATSHR | |
| SCHEMBL395557 | 0.72 | KIF11 (0.39) | — | |
| SCHEMBL7879895 | 0.72 | NOTUM (0.33) | GLAPOLBGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6495540-B2 | HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR | BRISTOL - MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | claimed |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-24 | — | — | US | claimed |
| US-6495540-B2 | HEXAHYDROAZEPINE-2-ONE DERIVATIVE AS BETA-AMYLOID INHIBITOR | BRISTOL - MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-24 | — | — | US | disclosed |
| US-5643925-A | COGNITION ACTIVATORS AND NERVE GROWTH FACTORS | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5614521-A | NERVE GROWTH FACTOR | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0501656-B1 | New benzene derivatives having (NGF) production-promoting activity | SANKYO CO (JP) | 1997-01-22 | — | — | EP | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010172-A1 | Lactams as inhibitors of A-beta protein production | BACE1, APP, APH1A | GLA 29/4885POLB 1879/4885GAA 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.